These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24367492)

  • 1. RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.
    Keilty D; Buchanan M; Ntapolias K; Aleynikova O; Tu D; Li X; Shepherd L; Bramwell V; Basik M
    PLoS One; 2013; 8(12):e81740. PubMed ID: 24367492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.
    Lundgren K; Holm K; Nordenskjöld B; Borg A; Landberg G
    Breast Cancer Res; 2008; 10(5):R81. PubMed ID: 18823530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
    Lundgren K; Brown M; Pineda S; Cuzick J; Salter J; Zabaglo L; Howell A; Dowsett M; Landberg G;
    Breast Cancer Res; 2012 Apr; 14(2):R57. PubMed ID: 22475046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
    Brown LA; Johnson K; Leung S; Bismar TA; Benítez J; Foulkes WD; Huntsman DG
    Breast Cancer Res Treat; 2010 Jun; 121(2):347-54. PubMed ID: 19636701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
    Jirström K; Stendahl M; Rydén L; Kronblad A; Bendahl PO; Stål O; Landberg G
    Cancer Res; 2005 Sep; 65(17):8009-16. PubMed ID: 16140974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.
    Beelen K; Opdam M; Severson T; Koornstra R; Vincent A; Wesseling J; Sanders J; Vermorken J; van Diest P; Linn S
    BMC Cancer; 2018 Jul; 18(1):761. PubMed ID: 30041599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
    Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification.
    Tabarestani S; Ghaderian SM; Rezvani H; Mirfakhraie R; Ebrahimi A; Attarian H; Rafat J; Ghadyani M; Alavi HA; Kamalian N; Rakhsha A; Azargashb E
    Cell Oncol (Dordr); 2014 Apr; 37(2):107-18. PubMed ID: 24573687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].
    Petráková K; Nenutil R; Grell P; Fabian P; Zichová I; Svoboda M; Palácová M; Vyzula R
    Klin Onkol; 2008; 21(5):303-8. PubMed ID: 19202962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and Predictive Value of
    Jeffreys SA; Becker TM; Khan S; Soon P; Neubauer H; de Souza P; Powter B
    Front Endocrinol (Lausanne); 2022; 13():895729. PubMed ID: 35784572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC).
    Yan Y; Li X; Blanchard A; Bramwell VH; Pritchard KI; Tu D; Shepherd L; Myal Y; Penner C; Watson PH; Leygue E; Murphy LC
    Ann Oncol; 2013 Aug; 24(8):1986-93. PubMed ID: 23579816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.
    Love RR; Duc NB; Havighurst TC; Mohsin SK; Zhang Q; DeMets DL; Allred DC
    J Clin Oncol; 2003 Feb; 21(3):453-7. PubMed ID: 12560434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
    Mrhalová M; Kodet R; Strnad P
    Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer.
    Aleksakhina SN; Kramchaninov MM; Mikushina AD; Kubrina SE; Petkau VV; Ivantsov AO; Moiseyenko VM; Imyanitov EN; Iyevleva AG
    Clin Transl Oncol; 2021 Apr; 23(4):874-881. PubMed ID: 32880048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
    Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
    Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
    Brennan DJ; Laursen H; O'Connor DP; Borgquist S; Uhlen M; Gallagher WM; Pontén F; Millikan RC; Rydén L; Jirström K
    Breast Cancer Res; 2011 Jan; 13(1):R12. PubMed ID: 21281480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.